A multinational, multicenter, open-label, single-assignment extension of the MS-LAQ-301 (ALLEGRO) study, to evaluate the long-term safety, tolerability and effect on disease course of daily oral laquinimod 0.6 mg in subjects with relapsing multiple sclerosis -

Phase 1

• Conditions: aquinimod is developed for the treatment of relapsing remitting multiple sclerosis.; MedDRA version: 9.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosis

• Registration Number: EUCTR2009-012989-30-FR
• Lead Sponsor: Teva Pharmaceutical Industries Ltd

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2009-09-22
• Last Update Posted: 21 August 2017

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

1.Subjects must have completed the Termination visit of MS-LAQ-301 (completion of all Termination visit activities) according to the MS-LAQ-301 protocol.
2.Women of child-bearing potential must practice an acceptable method of birth control during the study and up to 30 days after the last dose of the study drug. Hormonal contraception must be accompanied by an additional barrier method of birth control (male or female condom, diaphragm with spermicide).
3.Subjects must be willing and able to comply with the protocol requirements for the duration of the study.
4.Subjects must be able to comprehend, sign and date a written informed consent prior to entering the MS-LAQ-301E study.

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Exclusion Criteria:
1.Premature discontinuation from the MS-LAQ-301 study, for any reason.
2.Pregnancy [according to urine dipstick ß-HCG test performed at Baseline (Month 0E) visit] or breastfeeding.
3.Subjects with clinically significant or unstable medical or surgical condition detected or worsened during the MS-LAQ-301 study, which preclude safe participation and completion of the MS-LAQ-301E study. Acute exacerbation of MS will not exclude participation in the MS-LAQ-301E study.
4.Use of inhibitors of CYP3A4 within 2 weeks prior to baseline visit (V0E, Month 0E).

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified